Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23233662)

1.

Genome-wide study of methotrexate clearance replicates SLCO1B1.

Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, Martin PL, Cheng C, Devidas M, Pui CH, Evans WE, Hunger SP, Loh M, Relling MV.

Blood. 2013 Feb 7;121(6):898-904. doi: 10.1182/blood-2012-08-452839. Epub 2012 Dec 11.

2.

Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.

Zhang HN, He XL, Wang C, Wang Y, Chen YJ, Li JX, Niu CH, Gao P.

Pediatr Blood Cancer. 2014 Dec;61(12):2203-7. doi: 10.1002/pbc.25191. Epub 2014 Aug 17.

PMID:
25130190
3.

[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].

Zhang H, He X, Li J, Wang Y, Wang C, Chen Y, Niu C, Gao P.

Zhonghua Er Ke Za Zhi. 2014 Oct;52(10):770-6. Chinese.

PMID:
25537545
4.

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.

Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV.

J Clin Oncol. 2009 Dec 10;27(35):5972-8. doi: 10.1200/JCO.2008.20.4156. Epub 2009 Nov 9.

5.

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.

Ramsey LB, Bruun GH, Yang W, Treviño LR, Vattathil S, Scheet P, Cheng C, Rosner GL, Giacomini KM, Fan Y, Sparreboom A, Mikkelsen TS, Corydon TJ, Pui CH, Evans WE, Relling MV.

Genome Res. 2012 Jan;22(1):1-8. doi: 10.1101/gr.129668.111. Epub 2011 Dec 6.

6.

High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.

Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T.

Clin Pharmacol Ther. 2006 Nov;80(5):468-76.

PMID:
17112803
7.

Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.

Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Piñan MA, Garcia-Miguel P, Navajas A, Garcia-Orad A.

Pediatr Blood Cancer. 2011 Oct;57(4):612-9. doi: 10.1002/pbc.23074. Epub 2011 Mar 8.

PMID:
21387541
8.

Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.

Csordas K, Lautner-Csorba O, Semsei AF, Harnos A, Hegyi M, Erdelyi DJ, Eipel OT, Szalai C, Kovacs GT.

Br J Haematol. 2014 Aug;166(3):410-20. doi: 10.1111/bjh.12886. Epub 2014 Apr 9.

PMID:
24712521
9.

Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.

Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, García MJ.

Clin Pharmacokinet. 2006;45(12):1227-38.

PMID:
17112298
10.

Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.

Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Möricke A, Stanulla M, Schrappe M, Langer T.

Blood. 2013 Jun 27;121(26):5145-53. doi: 10.1182/blood-2013-01-480335. Epub 2013 May 7.

11.

Renal function and methotrexate clearance in children with newly diagnosed leukemia.

Murry DJ, Synold TW, Pui CH, Rodman JH.

Pharmacotherapy. 1995 Mar-Apr;15(2):144-9.

PMID:
7624260
12.

Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.

Yang JJ, Cheng C, Devidas M, Cao X, Campana D, Yang W, Fan Y, Neale G, Cox N, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Bowman WP, Camitta B, Reaman GH, Carroll WL, Willman CL, Hunger SP, Evans WE, Pui CH, Loh M, Relling MV.

Blood. 2012 Nov 15;120(20):4197-204. doi: 10.1182/blood-2012-07-440107. Epub 2012 Sep 24.

13.
14.
15.
16.

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.

Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds SB, Neale G, Treviño LR, French D, Campana D, Downing JR, Evans WE, Pui CH, Devidas M, Bowman WP, Camitta BM, Willman CL, Davies SM, Borowitz MJ, Carroll WL, Hunger SP, Relling MV.

JAMA. 2009 Jan 28;301(4):393-403. doi: 10.1001/jama.2009.7.

17.

[Pharmacokinetics of methotrexate in children with acute lymphoblastic leukemia].

Lares-Asseff I, Paredes R, Taboada C, Cravioto J, Velázquez M, Roldán RM, Faisal AG.

Bol Med Hosp Infant Mex. 1988 Oct;45(10):671-80. Spanish. No abstract available.

PMID:
3264171
18.

Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.

Rodman JH, Sunderland M, Kavanagh RL, Ochs J, Yalowich J, Evans WE, Rivera GK.

Cancer Res. 1990 Jul 15;50(14):4267-71.

19.

Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.

Donelli MG, Zucchetti M, Robatto A, Perlangeli V, D'Incalci M, Masera G, Rossi MR.

Med Pediatr Oncol. 1995 Mar;24(3):154-9.

PMID:
7838036
20.

Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.

Zgheib NK, Akra-Ismail M, Aridi C, Mahfouz R, Abboud MR, Solh H, Muwakkit SA.

Pharmacogenet Genomics. 2014 Aug;24(8):387-96. doi: 10.1097/FPC.0000000000000069.

PMID:
25007187
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk